Everolimus-eluting versus biolimus-eluting stents with biodegradable polymers in unselected patients undergoing percutaneous coronary intervention: five-year results of the randomised, non-inferiority SORT OUT VIII trial
Primary result · TLF (cardiac death, myocardial infarction not clearly attributable to a non-target lesion, or target lesion revascularisation)Result — go to the resultRelative risk 0.88 95% CI 0.71–1.10Authors' conclusion
At 5-year follow-up, TLF was comparable for EES and BES. The incidence of myocardial infarction, however, was lower in patients randomised to EES versus BES implantation.
Study context
- Population
- Patients with a clinical indication for percutaneous coronary interventionpatients included
- Participants
- 2,764 patients
- Comparison
- EES versus BES
- EESn = 1,385
- BESn = 1,379reference
Methodological detailsthree sites in Western Denmark, randomly assigned (1:1)
- Three sites in Western Denmark
- Randomly assigned (1:1)
Primary result
As reported in the abstract
TLF (cardiac death, myocardial infarction not clearly attributable to a non-target lesion, or target lesion revascularisation) · 5-year follow-up
Relative risk
0.88
95% CI 0.71–1.10
Events by treatment group
EES vs BES
RR 0.88 (95% CI 0.71–1.10)
Further findings
| Outcome | EES | BES | RR (95% CI) | |
|---|---|---|---|---|
| Myocardial infarction · 5-year follow-upLower in the EES group | 6.1% | 8.4% | 0.71 (0.54–0.95) | |
| Very late stent thrombosis · 5-year follow-upRare for both stent types | 0.9% | 0.7% | 1.32 (0.56–3.14) | |
| 0.20.5125Relative risk (log scale) |
Original publication
Everolimus-eluting versus biolimus-eluting stents with biodegradable polymers in unselected patients undergoing percutaneous coronary intervention: five-year results of the randomised, non-inferiority SORT OUT VIII trial. EuroIntervention. Published 2 June 2025. doi:10.
Summarised from the published abstract; every number is checked against it